41 results about "Insulin deficiency" patented technology

The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, or narrow spectrum antibiotics / anti-bacterial agents that are capable of restoring healthy mammalian bacterial gastrointestinal microbiota.

Pharmaceutical compositions that include an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating an insulin deficiency in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

The subject invention pertains to an implantable therapeutic device for treating diabetes and methods of making. Upon implantation, the present device secretes insulin in response to blood glucose levels, exquisitely regulates blood glucose levels, reduces hyperglycemia, and includes β-cell regeneration in the host. It is useful for treating or ameliorating diabetes or diabetic conditions of a subject, including but not limited to, type 1 diabetes mellitus, hyperglycemia, impaired glucose tolerance, insulin deficiency, elevated glucose levels, and insulin resistance.

The invention relates to methods of isolating differentiable fetal-derived cells from various tissues of the placenta. Specifically, some of the methods of the present invention relate to isolating differentiable amnion-derived cells, while other methods of the present invention relate to isolating differentiable chorion-derived cells. The present invention also relates to methods of inducing these isolated differentiable amnion-derived and differentiable chorion-derived cells to at least partially differentiate. The present invention also relates to methods of treating insulin deficiencies in a subject by administering these differentiable amnion-derived cells and / or differentiable chorion-derived cells to subjects in need thereof.

The present invention relates to a class of indolylquinone compounds that inhibit GRB-2 adaptor protein function, pharmaceutical compositions comprising these compounds, and methods for ameliorating the symptoms of cell proliferative disorders associated with GRB-2 adaptor protein function using these compounds. The present invention further relates to methods for treating insulin-related disorders, such as diabetes, insulin resistance, insulin deficiency and insulin allergy, and for ameliorating the symptoms of insulin-related disorders, using certain indolylquinone compounds and pharmaceutical compositions thereof. The present invention also relates to novel synthetic methods for the preparation of mono- and bis-indolylquinone compounds.

Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. Coxsackie virus has been detected in human pancreatic beta cells and causes insulitis. This non-destructive islet inflammation does not itself cause diabetes, but this disease will occur if viral infection is followed by a separate autoimmune response. The insulitis is mediated mainly by natural killer cells. Islets from coxsackie virus positive samples displayed reduced insulin secretion in response to glucose and other secretagogues. Virus extracted from positive islets was able to infect beta cells from human islets of non-diabetic donors, causing viral inclusions and signs of pyknosis.

Pharmaceutical compositions that include insulin, an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component or a bile salt component without a fatty acid component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1. Methods of treating an insulin deficiency in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and / or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor.

The present invention relates to a controller unit and methods for controlling an insulin pump. The controller unit includes a user input that receives a gain factor. The gain factor has been calculated based on historical data in relation to a patient. The controller unit includes a measurement input for receiving data representative of a measured blood glucose level for the patient. Processing logic of the controller unit is configured to apply the measured blood glucose level to a pancreatic beta-cell insulin secretion computational model to predict an insulin output level, apply the gain factor to the predicted insulin output level to determine a patient insulin deficiency level, and calculate a control signal for controlling the insulin output level of the insulin pump based on the patient insulin deficiency level.; Methods are provided for optimising the gain factor based on the historical data in relation to the patient.

Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and / or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease by administration of antisense compounds targeted to PTPRU.

The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within.

The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within.

The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within.

The invention features a method of treating deficiency of insulin in a patient, comprising administering to a patient in need thereof hedgehog protein or nucleic acid in an amount effective to raise the level of insulin in the patient.

The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within.

The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within.

The invention belongs to the technical field of medicines and relates to a traditional Chinese medicine composition for treating diabetes and a preparation method thereof. The traditional Chinese medicine composition for treating diabetes comprises 3-7 parts by weight of pseudo-ginseng, 1-5 parts by weight of cassia seeds, 4-8 parts by weight of mulberry leaves, 1-5 parts by weight of root of kudzu vine, 1-5 parts by weight of chrysanthemum, 4-8 parts by weight of hairyvein agrimony, 1-5 parts by weight of radix polygonati officinalis, 1-5 parts by weight of bark of eucommia, 1-5 parts by weight of tender leaves and stems of Laifeng Ampelopsis grossedentata, 1-5 parts by weight of radix astragali, 1-5 parts by weight of cornus officinalis, 1-5 parts by weight of wolfberry, 1-5 parts by weight of Chinese yam Ximaoshanyao and 3-7 parts by weight of root of moringa oleifera. Through traditional Chinese medicine ingredient compatibility, the traditional Chinese medicine composition can effectively activate inert insulin, reduce blood sugar, make inert insulin recover activity and normally participate in glycometabolism, improve human body blood sugar utilization and conversion, realize stable reduction of blood sugar, protect islet cells, inhibit insulin deficiency, inhibit insulin excessive secretion when insulin for glycometabolism is increased, relieve pancreas burden, realize pancreas necessary rest and reorganization, protect pancreas and inhibit islet failure.

The invention discloses a Chinese herbal medicine composition for treating diabetes and a preparation method and an administration method thereof, and belongs to the field of Chinese herbal medicines.The Chinese herbal medicine composition for treating the diabetes is prepared from the following components in parts by weight: 1 to 5 parts of ramuli euonymi, 15 to 30 parts of radix astragali, 10 to 30 parts of fructus lycii, 1 to 10 parts of rhizoma dioscoreae, 10 to 30 parts of cortex lycii radicis, 10 to 20 parts of radix puerariae lobatae, 20 to 40 parts of tartary buckwheat, 10 to 30 partsof radix trichosanthis, and 1 to 10 parts of semen litchi. The Chinese herbal medicine composition has the advantages that under the cooperation function between the special components, the diabetesand complications thereof due to insulin deficiency can be effectively treated and prevented; the self insulin secretion ability of a patient is enhanced; the purpose of synchronous prevention and treatment is realized.

The invention belongs to the technical field of medicines and relates to a traditional Chinese medicine composition for treating hyperglycemia and diabetes and a preparation method thereof. The traditional Chinese medicine composition for treating hyperglycemia and diabetes comprises 3-7 parts by weight of pseudo-ginseng, 1-5 parts by weight of cassia seeds, 4-8 parts by weight of yew leaves, 1-5 parts by weight of watermelon peel, 1-5 parts by weight of corn stigma, 4-8 parts by weight of cacumen biotae, 1-5 parts by weight of radix polygonati officinalis, 1-5 parts by weight of bark of bark of eucommia, 1-5 parts by weight of tender leaves and stems of Laifeng Ampelopsis grossedentata, 1-5 parts by weight of rhizoma polygonati, 1-5 parts by weight of cornus officinalis, 1-5 parts by weight of wolfberry, 1-5 parts by weight of Chinese yam Ximaoshanyao and 3-7 parts by weight of root of moringa oleifera. Through traditional Chinese medicine ingredient compatibility, the traditional Chinese medicine composition can effectively activate inert insulin, reduce blood sugar, make inert insulin recover activity and normally participate in glycometabolism, improve human body blood sugar utilization and conversion, realize stable reduction of blood sugar, protect islet cells, inhibit insulin deficiency, inhibit insulin excessive secretion when insulin for glycometabolism is increased, relieve pancreas burden, realize pancreas necessary rest and reorganization, protect pancreas and inhibit islet failure.

The invention provides a method allowing reverse differentiation of human somatic cells for generation of autologous pancreatic stem cells and autologous pancreas islet. The method is as follows: culture solutions containing extractives of different plants and different protein components are used to culture human somatic cells step by step, which enables the somatic cells to generate autologous pancreatic stem cells through reverse differentiation, and autologous pancreas islet is generated through further culture. The method provided in the invention enables the first generation of autologous pancreatic stem cells and autologous pancreas islet at a magnitude order of tens of billions to be generated within two to three weeks. The plant and protein-induced human autologous pancreatic stem cells have similar cell specific phenotypes and a plurality of cell differentiation capability as those of human natural pancreatic stem cells; the autologous pancreatic stem cells and autologous pancreas islet cells have immense potential both in the application field of treatment of pancreatic diseases like insulin deficiency type diabetes and in the engineering field of autologous pancreatic tissue; the invention is also applicable to establishment of novel autologous pancreatic stem cell libraries and long-term permanent preservation of autologous pancreatic stem cells.

Disclosed herein are compounds, compositions and methods for modulating the expression of LMW-PTPase in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and / or treatment of diabetes, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, and hyperfattyacidemia. In some embodiments, the diabetes is type II diabetes by administration of antisense compounds targeted to LMW-PTPase.

The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within.

The invention discloses a construction method of an I-type diabetes large animal model, and belongs to the technical field of biomedical therapies. According to the construction method, pigs with widesources serve as modeling experimental animals of the I-type diabetes large animal model and are injected with a dosage of 110-130 mg / kg streptozotocin, pig pancreas beta cells are selectively damaged to suffer from autoimmune destruction to cause insulin deficiency, and thus the I-type diabetes large animal model is constructed. The construction method has the advantages of being convenient in modeling, low in cost, wide in source and high in similarity, animal survival rate and model establishing success rate, and provides ideal experimental animal models for pathogenesis, treatment means and drug development and use of I-type diabetes.

The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and / or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor.

The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and / or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor.

The invention belongs to the technical field of medicines and relates to a traditional Chinese medicine for treating diabetes and a preparation method thereof. The traditional Chinese medicine for treating diabetes comprises 3-7 parts by weight of Taishan wild ganoderma lucidum, 1-5 parts by weight of trachycarpus fruit, 4-8 parts by weight of mulberry leaves, 1-5 parts by weight of root of kudzu vine, 1-5 parts by weight of chrysanthemum, 4-8 parts by weight of fresh polygomun aviculane, 1-5 parts by weight of radix polygonati officinalis, 1-5 parts by weight of bark of eucommia, 1-5 parts by weight of tender leaves and stems of Laifeng Ampelopsis grossedentata, 1-5 parts by weight of radix astragali, 1-5 parts by weight of cornus officinalis, 1-5 parts by weight of wolfberry, 1-5 parts by weight of Chinese yam Ximaoshanyao and 3-7 parts by weight of peanut rhizome. Through traditional Chinese medicine ingredient compatibility, the traditional Chinese medicine can effectively activate inert insulin, reduce blood sugar, make inert insulin recover activity and normally participate in glycometabolism, improve human body blood sugar utilization and conversion, realize stable reduction of blood sugar, protect islet cells, inhibit insulin deficiency, inhibit insulin excessive secretion when insulin for glycometabolism is increased, relieve pancreas burden, realize pancreas necessary rest and reorganization, protect pancreas and inhibit islet failure.

The present disclosure provides compositions and methods for treating an insulin deficiency (ID) disorder or associated symptom in a subject in need thereof, the compositions comprising S100 calcium binding protein A9 (S100A9), a variant or fragment of S100 calcium binding protein A9, and insulin, a variant or fragment of insulin.